The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The FDA grants SY-1425 Orphan Drug Designation for the treatment of AML
On 21st August 2017, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to SY-1425 (tamibarotene) for the treatment of patients with Acute Myeloid Leukemia (AML).1
Highly specialized regions known as super-enhancers, associated with selective Retinoic Acid Receptor Alpha (RARα) and Monocyte Specific Factor (IRF8) genes, have been identified in blast cells of some patients with AML. These super-enhancers have been shown to drive high expression of RARα and IRF8, thus driving AML blasts to be in an immature, undifferentiated, and proliferative state. SY-1425 is an oral, first-in-class, selective RARα agonist. SY-1425 binds to RARα, which leads to reactivation of differentiation and prolongation of survival in preclinical models of AML with high RARα expression.2
Currently, SY-1425 is being evaluated in a biomarker directed phase II study (NCT02807558) aiming to assess its safety and efficacy alone or in combination with azacitidine in newly diagnosed or relapsed/refractory AML patients who are positive for either RARα or IRF8. The primary endpoint of the study is Overall Response Rate (ORR).
References
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?